Achieving remission from depression with venlafaxine and venlafaxine extended release: A literature review of comparative studies with selective serotonin reuptake inhibitors

Acta Psychiatrica Scandinavica, Supplement

Volumn 106, Issue 415, 2002, Pages 24-30

  Rudolph, Richard L ^a  

^a Cyberonics Inc   (Italy)

Author keywords

Major depressive disorder; Remission; Selective serotonin reuptake inhibitors; Venlafaxine XR

Indexed keywords

FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; HAMILTON SCALE; HUMAN; META ANALYSIS; REMISSION; COMPARATIVE STUDY; DYSTHYMIA; MAJOR DEPRESSION; MEDICAL LITERATURE; MELANCHOLIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RATING SCALE; SYSTEMATIC REVIEW; ARTICLE; DELAYED RELEASE FORMULATION; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; HUMANS; MULTICENTER STUDIES; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0036977691     PISSN: 00651591     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.106.s415.5.x     Document Type: Conference Paper

References (34)

1. KELLER MB, LAVORI PW, MUELLER TI et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-816.
2. SHEA MT, ELKIN I, IMBER SD et al. Course of depressive symptoms over follow-up. Findings from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Arch Gen Psychiatry 1992;49:782-787.
3. FERRIER IN. Treatment of major depression: is improvement enough? J Clin Psychiatry 1999;60 (Suppl. 6):10-14.
4. FRANK E, PRIEN RF, JARRETT RB et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, Recovery, Relapse, and Recurrence. Arch Gen Psychiatry 1991;48:851-855.
5. KUPFER DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52 (Suppl. 5):28-34.
6. MILLER IW, KEITNER GI, SCHATZBERG AF et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608-619.
7. PAYKEL ES, RAMANA R, COOPER Z, HAYHURST H, KERR J, BAROCKA A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25:1171-1180.
8. BARRACLOUGH B, BUNCH J, NELSON B, SAINSBURY P. A hundred cases of suicide: clinical aspects. Br J Psychiatry 1974;125:355-373.
9. MONTGOMERY SA, MONTGOMERY D. Pharmacological prevention of suicidal behaviour. J Affect Disord 1982;4:291-298.
10. BALLENGER JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999;60 (Suppl. 22):29-34.
11. NIERENBERG AA, WRIGHT EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999;60 (Suppl. 22):7-11.
12. STAHL SM. Are two antidepressant mechanisms better than one? J Clin Psychiatry 1997;58:339-340.
13. THASE ME. Treatment of severe depression. J Clin Psychiatry 2000;61 (Suppl, 1):17-25.
14. HARVEY AT, RUDOLPH RL, PRESKORN SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000;57:503-509.
15. CUNNINGHAM LA, for the Venlafaxine XR 208 Study Group. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry 1997;9:157-164.
16. ENTSUAH R, CHITRA R. A benefit - risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull 1997;33:671-676.
17. HOLLIDAY SM, BENFIELD P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-294.
18. HORST WD, PRESKORN SH. The pharmacology and mode of action of venlafaxine. Rev Contemp Pharmacother 1998;9:293-302.
19. DANJOU P, HACKETT D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995;10 (Suppl. 2):15-20.
20. KIENKE AS, ROSENBAUM JF. Efficacy of venlafaxine in the treatment of severe depression. Depress Anxiety 2000;12 (Suppl. 1):50-54.
21. DIERICK M, RAVIZZA L, REALINI R, MARTIN A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:57-71.
22. GUELFI JD, WHITE C, HACKETT D, GUICHOUX JY, MAGNI G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-458.
23. RUDOLPH RL, FABRE LF, FEIGHNER JP, RICKELS K, ENTSUAH R, DERIVAN AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998;59:116-122.
24. SILVERSTONE PH, RAVINDRAN A, for the Venlafaxine XR 360 Study Group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999;60:22-28.
25. CLERC GE, RUIMY P, VERDEAU-PAILLIÈS J, on behalf of the Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-143.
26. RUDOLPH RL, FEIGER AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171-181.
27. BALLÚS C, QUIROS G, DE FLORES T et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 2000;15:43-48.
28. MEHTONEN O-P, SøGAARD J, ROPONEN P, BEHNKE K, for the Venlafaxine 631 Study Group. Randomized, double-blind comparison of venlafaxine and sertraline in out-patients with major depressive disorder. J Clin Psychiatry 2000;61:95-100.
29. POIRIER M-F, BOYER P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 1999;175:12-16.
30. TZANAKAKI M, GUAZZELLI M, NIMATOUDIS I, ZISSIS NP, SMERALDI E, RIZZO F. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia [erratum published Int Clin Psychopharmacol 2000; 15: 120]. Int Clin Psychopharmacol 2000;15:29-34.
31. THASE ME, ENTSUAH AR, RUDOLPH RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241.
32. DANISH UNIVERSITY ANTIDEPRESSANT GROUP. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299.
33. ANDERSON IM. SSRIs versus tricyclic antidepressants in depressed inpatients, a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7 (Suppl. 1):11-17.
34. ANDREWS JM, NEMEROFF CB. Contemporary management of depression. Am J Med 1994;97:24S-32S.